MetrioPharm AG Obtains Patent Protection for its Lead Compound MP1032 in Brazil
Zurich, July 07, 2021. MetrioPharm AG, a pharmaceutical company developing drugs for chronic inflammatory diseases, announces that a further substance patent has been obtained for its lead compound MP1032. The Brazilian patent BR 112012021857-3 was granted on June 22, 2021.
Therefore, MetrioPharm AG has now attained comprehensive protection for MP1032 in another relevant market. In addition to Europe, the US, Canada, Australia, New Zealand, Israel, China, Japan, Russia, South Africa and the Republic of Korea, the entire American continent is currently covered including Brazil, the largest country in South America.
“The granting of the Brazilian patent is a further success of our continuously driven patent work. According to the market research institute IQVIA, Brazil was considered the seventh largest pharmaceutical market worldwide in 2018 and is expected to rank fifth, ahead of France and Italy, by 2023, with annual growth rates of 5 percent to 8 percent. The granting of patents in a country such as Brazil is naturally also an important component for our global strategy,” commented Dr. Wolfgang Brysch, CEO of MetrioPharm AG.
About MetrioPharm AG
MetrioPharm AG is a pharmaceutical development company focusing on drugs for chronic inflammatory diseases such as psoriasis, arthritis, and multiple sclerosis. Such chronic diseases pose the greatest individual health risk. The goal of MetrioPharm AG is to make the therapy of chronic inflammatory diseases more effective and more tolerable. We hope to achieve a healthspan expansion for patients: We want to stop the progression of chronic inflammatory diseases as early as possible and significantly prolong the healthy lifespan of millions of people.
MetrioPharm was founded in 2007 with headquarters in Zurich. The company has its R&D activities in Berlin.
About MP1032
MP1032 is the lead compound of a class of proprietary immune modulators developed by MetrioPharm AG. MP1032 is believed to modulate the oxidative stress-mediated activation state of macrophages and downregulate the M1 state. In contrast to other immune-modulating and disease-modifying drugs, MP1032 does not impact T-cells and preferentially affects macrophages at the sites of inflammation. MP1032 has shown anti-inflammatory activity in animal models of disease and a favorable toxicology profile in pre-clinical studies.
For the first Phase II study with MP1032, the indication psoriasis was selected because this immune-induced inflammatory disease is regarded as a so-called »door-opener indication«. Successes in the treatment of psoriasis have already led to first indications of promise for use in other chronic inflammatory diseases, such as arthritis and multiple sclerosis.
In a preclinical study published in the International Journal of Molecular Science, MP1032 was shown to exert both potent immunomodulatory effects on ROS and SARS-CoV-2-specific antiviral properties. MetrioPharm's lead compound thus has the potential to both slow viral spread in the body and alleviate Covid-19 symptoms. A Phase II clinical trial in Covid-19 patients is being prepared for the first half of 2021.
Forward-looking statements
This press release contains forward-looking statements that involve risks and uncertainties and are consistent with MetrioPharm AGs assessment as of the date of this release. Such forward-looking statements are neither promises nor guarantees, but are subject to numerous risks and uncertainties, many of which are beyond MetrioPharm AGs control, that could cause actual results to differ materially from those contemplated in these forward-looking statements. MetrioPharm does not assume any obligation to update forward-looking statements with respect to changed expectations or new events, conditions or circumstances on which these statements are based. A liability or guarantee and, if applicable, claims for topicality, correctness and completeness of these data and information are excluded and cannot be derived either explicitly or impliedly.
Your Contact:
 |
|
Lia Petridou T +49 (0) 30 33 84 395 53 |
